The truth about this vertical
Biotech companies often reorganize around a particular asset by creating a spinoff to house a specific program, creating a company to raise financing for a specific asset, or establishing an international subsidiary in anticipation of a regional trial or commercial launch. Each of these events creates a legal entity that must be reflected in the financial reporting of the company, frequently on a compressed timeline driven by a financing or regulatory deadline.
Companies that manage this on a single-entity accounting system end up tracking the new entity’s activity in a parallel spreadsheet. Intercompany transactions are manually reconciled and consolidated financials are assembled by hand each period, a process that gets more fragile with every entity added.
How NetSuite can help
For this type of multi-entity structure NetSuite’s OneWorld functionality is built-in, supporting intercompany transaction management, automated elimination at consolidation, multi-currency for international subsidiaries, and financial statements at the entity level as well as the consolidated view. With the right setup, adding a new subsidiary is not a one-off project each time, but a defined onboarding process.
This is especially true when you are in a hurry. A biotech spinning off an asset-specific entity ahead of a financing round does not have months to build clean accounting for the new structure; the system has to be ready to support it on the timeline the deal needs.
Why Archer Insights?
Archer Insights has built the multi-entity capability within NetSuite for the life sciences structure where a new entity is often created to hold specific program IP, separate cap tables and compliance obligations from day one. That experience means the entity structure is built to scale before the next spin-off happens, not rebuilt every time one does.